Search Results for: CLINICAL TRIALS Its Time to
Articles
Insilico Medicine Identified Multiple New Targets for ALS Using its AI-Driven Target Discovery Engine July 7, 2022
Insilico Medicine recently announced the company has identified multiple unreported potential therapeutic targets for amyotrophic lateral sclerosis (ALS), using its proprietary AI-driven target discovery engine….
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy June 29, 2022
Neurona Therapeutics recently announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study…..
Akoya Biosciences to Partner With Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature Test Into a Companion Diagnostic June 28, 2022
Akoya Biosciences, Inc. and Acrivon Therapeutics, Inc. recently announced an agreement to co-develop, validate, and commercialize Acrivon’s OncoSignature test, a first-of-its-kind...Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next-Generation Core Inhibitor June 6, 2022
Assembly Biosciences, Inc. recently announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor...CLINICAL TRIALS SOLUTIONS - Cracking Down on the Rising Costs of Drug Development: How Pinpointing the Complexity of Individual Patients Can Improve Success Rates June 1, 2022
Dominique Demolle, PhD, and Erica Smith, PhD, say taking a more holistic, patient-centric approach by considering patients’ individual psychology, perceptions, and beliefs provides drug developers the opportunity to quantify these interpersonal differences between patients and address this source of variability in data analysis and interpretation.
Lonza Completes Dedicated Early Clinical Phase Development & Manufacturing Facility in Bend (OR) June 1, 2022
Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early...Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress May 27, 2022
Hepion Pharmaceuticals, Inc. recently announced that its Chief Medical Officer, Todd Hobbs, MD, gave a clinical presentation titled Recofilstat (CRV431):...Pharmazz Inc. Announces Positive Results of Phase 3 Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke May 25, 2022
Pharmazz, Inc. recently announced positive topline results of its Phase 3 clinical trial evaluating sovateltide as a treatment for acute ischemic stroke. The data at 90 days showed….
Clearmind Medicine & SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment May 24, 2022
Clearmind Medicine Inc. recently announced positive safety profile results from its joint preclinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind’s proprietary psychedelic molecule….
Akston Biosciences Doses First Participants in Phase 2 Clinical Trial for Shelf-Stable COVID-19 Booster May 12, 2022
Akston Biosciences Corporation recently announced it dosed the first set of volunteers in an open-label study of AKS-452, its protein...Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial May 10, 2022
Evaxion Biotech A/S recently announced it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in...Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant in Phase 2b NASH Trial May 3, 2022
Hepion Pharmaceuticals, Inc. recently announced it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with...ARTIFICIAL INTELLIGENCE - Modernizing Your Clinical Development Safety Practices With Artificial Intelligence May 2, 2022
Updesh Dosanjh, MS, says by continuing to explore the ability of these technologies to deliver better and safer treatments, pharmaceutical companies can benefit not only the advancement of the medical community, but the quality of life of patients around the world.
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study for the Treatment of Osteogenesis Imperfecta April 20, 2022
Ultragenyx Pharmaceutical Inc. recently announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients….
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency April 12, 2022
Inozyme Pharma, Inc. recently announced the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in...Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of Drug-Enhanced Cell Therapy for the Treatment of Patients With Solid Tumors April 5, 2022
Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and….
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial April 4, 2022
Inozyme Pharma, Inc. recently announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the...Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development March 30, 2022
Qualigen Therapeutics, Inc. recently announced it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead...Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program March 21, 2022
Vallon Pharmaceuticals, Inc. recently announced topline results from its pivotal SEAL study evaluating ADAIR, a proprietary abuse-deterrent formulation of immediate...Travere Therapeutics Submits NDA for Sparsentan for the Treatment of IgA Nephropathy March 21, 2022
Travere Therapeutics, Inc. recently announced it has submitted a New Drug Application (NDA) to the US FDA under Subpart H...
